Dukes Iain D. 4
4 · Traws Pharma, Inc. · Filed Mar 10, 2026
Research Summary
AI-generated summary of this filing
Traws Pharma CEO Iain Dukes Receives Stock Award (231,336)
What Happened
Iain D. Dukes, CEO of Traws Pharma, received a grant of 231,336 derivative securities on March 8, 2026. The reported price is $0.00 (total $0 on Form 4) and the award is described in the filing as stock options/awards issued under the company’s 2021 Incentive Compensation Plan.
Key Details
- Transaction date: 2026-03-08; Form 4 filed: 2026-03-10 (filed within the typical 2-business-day window).
- Securities: 231,336 derivative shares (stock option/award) reported at $0.00 per share.
- Vesting: Footnote states the award vests 100% on the first anniversary of the grant date.
- Shares owned after transaction: not specified in the information provided on the Form 4.
- Footnote: Award was approved by the issuer’s compensation committee (comprised of independent directors) under the 2021 Incentive Compensation Plan.
Context
This was a grant/award of derivative securities (not an open-market purchase or sale). Grants to executives are common as compensation and typically vest over time; they do not represent immediate market purchases or sales. Because the grant vests in one year, the CEO must remain employed or meet any plan conditions to realize the shares/options.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-03-08+231,336→ 231,336 totalExercise: $1.60From: 2027-03-08Exp: 2036-03-08→ Common Stock (231,336 underlying)
Footnotes (1)
- [F1]Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.